HR-Positive Breast Cancer: Future Directions in Precision Endocrine Therapy

This final segment summarizes key themes and future directions in the management of hormone receptor–positive, HER2-negative breast cancer. Dr. Adam Brufsky invites closing reflections on how emerging therapies and biomarkers may shape clinical practice.

Dr. Hope S. Rugo highlights the growing role of oral selective estrogen receptor degraders and the potential to improve patient experience by reducing reliance on injectable therapies. She emphasizes that while these advances are promising, careful interpretation of emerging data and thoughtful integration into practice remain essential.

Dr. Mabel Mardones underscores the importance of optimizing sequencing strategies to maintain quality of life and delay chemotherapy, while also exploring new biomarker-driven approaches. Dr. Lisa Raff and Ms. Lori Brisbin emphasize the need for effective implementation, access, and data integration. Overall, this segment highlights a rapidly evolving landscape that requires balancing innovation with evidence-based care.